NORGINE TO DISCONTINUE PHASE II NRL972 TO DETECT LIVER DISEASE AND ASSESS SEVERITY OF LIVER DAMAGE

London. 25 July 2013. Norgine announced that following detailed data review and regulatory scientific advice, it has discontinued the development of NRL972, as a measure of liver transporter function.

Donna McVey Chief Development Officer at Norgine, said: "'Pipeline productivity is an industry-wide challenge and we remain focused on getting good results from all our other ongoing projects in the three therapy areas of focus, gastroenterology, hepatology and supportive care."

She added;" We have made considerable progress with our pipeline this year, with the European regulatory approval and launch of XIFAXAN ® (rifaximin) 550 for the reduction in recurrence of episodes of overt hepatic encephalopathy. We are also are progressing NRL001, a phase II compound intended for the treatment of faecal incontinence. It is believed that NRL001 will provide a new option for the treatment of this distressing condition which affects around 2 per cent of the general population.[i]"

Ends

About NRL 972

NRL972 is a compound which was being developed to detect liver disease, and to assess the severity of liver damage. Although various liver function tests currently exist, single tests mostly fail to detect early (mild) stages of liver disease, and do not allow the clinician to differentiate between stages of disease severity, or to characterise the progression or regression of disease. NRL972 was intended to be a validated diagnostic tool that specifically identifies early stages of the disease and the associated functional abnormalities.

About Norgine

Norgine is a successful, independent European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In

Norgine - Norgine House - Widewater Place
Moorhall Road - Harefield - Uxbridge - UB9 6NS - UK - Tel: +44 (0) 1895 826 600

2012, Norgine's net product sales were c€250 million and the company employs over 1,000 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology, critical and supportive care.

Key marketed products include:

- DANTRIUM® capsules to treat spasticity resulting from upper motor neuron disorders
- DANTRIUM® IV for the treatment for malignant hyperthermia, a life threatening condition
- KLEAN-PREP® for large bowel preparation prior to colonoscopy or surgery
- MOVICOL® for the treatment of constipation and faecal impaction
- MOVIPREP® a bowel preparation for use prior to any procedure that requires a clean colon
- ORAMORPH® for the treatment of moderate to severe pain associated with cancer
- PROTHER® special medical food for cancer patients
- SAVENE® an orphan drug for the treatment of rare consequence of using anthracyclines (anti-cancer treatments)
- SETOFILM® an orally dispersible film formulation of ondansetron
- XEROTIN® artificial saliva for the management of xerostomia (dry mouth)
- XIFAXAN® (XIFAXANTA®/TARGAXAN®) for the treatment of travellers' diarrhoea and the reduction in recurrence of episodes of overt hepatic encephalopathy.

Norgine owns a manufacturing and development site in Hengoed, UK and a manufacturing site in Dreux, France. For more information: www.norgine.com.

Media Contacts

Isabelle Jouin, Tel: +44 (0) 1895 453 643; Mobile: + 44 (0) 771 406 1327

[i] Kamm MA; Faecal incontinence. BMJ. 1998 Feb 14;316(7130):528-32.

Norgine - Norgine House - Widewater Place
Moorhall Road - Harefield - Uxbridge - UB9 6NS - UK - Tel: +44 (0) 1895 826 600